Global Edge launches three healthcare brands in Middle East and showcases their product lines at Arab Health 2025
The three new brands will empower individuals to make informed decisions and choices for a healthier future.
UAE: GE Services & Trading (Global Edge) a leading company serving as a gateway for businesses to expand to the GCC and MENA region, unveiled three innovative international healthcare brands – SRW®, eimele™ and Theronomic™ – at the Arab Health 2025 to cater to the growing demands for natural and effective healthcare solutions in the UAE and the Middle East region.
This move is in line with the UAE's vision to advance healthcare under the 'Forward Society' pillar of 'We the UAE 2031 Vision,' which seeks to establish an integrated and accessible healthcare system, enhance quality of life, and promote future-ready healthcare solutions. Through SRW®, anti-aging products, eimele™ plant-based products, and Theronomic™ tribiotic supplements, Global Edge seeks to empower customers and enhance access to world-class products that support healthy lifestyles.
SRW® ' Science Research Wellness ' offers a range of anti-aging products backed by scientific research. These products harness the power of natural ingredients to protect, repair, and rejuvenate cells, promoting longevity and vitality.
With over 3.1 billion people worldwide struggling to maintain a balanced diet and up to 87 per cent failing to consume enough fruits and vegetables, eimele™ offers a range of plant-based solutions to address these nutritional gaps. The products are packed with phytonutrients, providing customers with essential nutrients, supporting optimal health, and ensuring healthier lifestyles.
Theronomic™ TRIBIOTIC ® Gut Shield provides a comprehensive solution to gut health. By combining prebiotic, probiotic, and postbiotic ingredients, this innovative formula supports a
balanced microbiome, ensuring targeted health benefits. Each capsule of this product contains 30 billion CFU from multiple strains to promote better digestive health and enhanced immune system function.
Karim Hwalla, Director at Global Edge, stated: 'We are delighted to bring these innovative healthcare brands to the Middle East market. At Global Edge, we have emerged as a driving force and trusted leader in distribution and market entry. We believe that navigating successful market entry hinges on thorough research, a solid strategy, and dependable partnerships - principles that are deeply ingrained in everything we do. By aligning these elements with a practical and transparent approach, we have ensured that the journey of these new brands into the Middle East market was smooth and effective, especially by targeting events like Arab Health 2025.'
'Strategic location and supportive business environment of countries like UAE in the region make it an ideal platform for global brands to expand their reach. With its open market economy, economic stability, and support for private sector entities, the country offers innumerable opportunities for businesses to thrive. Hence, we are proud to support the UAE's vision to establish a world-class healthcare system,' he added
A recent McKinsey research highlighted the growing consumer interest in overall wellness, with a particular focus on health, fitness, nutrition, appearance, sleep, and mindfulness. The research also emphasised that more people are expected to increase their purchases of both wellness products and services over the next year, particularly those that emphasise physical and mental health.
This increasing demand for wellness products and services aligns with the offerings of the three brands launched by Global Edge. By introducing these brands, Global Edge aims to contribute
to the Middle East's growing healthcare sector and empower individuals to make informed decisions and choices for a healthier future.
-Ends-
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
6 days ago
- Khaleej Times
SEGA™ launched by elegant hoopoe as live system to disrupt global franchising
In a bold move poised to reshape the global franchise industry, elegant hoopoe, the international health-tech brand, has officially launched SEGA™ (Strategic Ecosystem Growth Architecture). This ground breaking framework is a legally registered, dynamic alternative to the static US Franchise Disclosure Document (FDD). This new franchise model goes far beyond traditional compliance paperwork. SEGA™ actively integrates legal structure, AI-powered CRM, clinical protocols, and investor architecture into one unified, intelligent system. It is purpose-built to scale transparent and efficient 360° wellness ecosystems globally. 'The world doesn't need more paperwork - it needs systems that reflect reality. SEGA™ is that system,' said Shahriar Shahir Barzegar, visionary entrepreneur and architect of the intelligent franchising model. Unlike traditional franchise models, SEGA™ is built upon seven volumes of detailed operational and strategic standards. Authored and published by elegant hoopoe, these volumes were officially registered with the UAE Ministry of Economy in 2022. These volumes serve as a comprehensive architectural blueprint for the elegant hoopoe ecosystem. They encompass everything from medical and clinical protocol design to AI-powered CRM and operational logic, global brand governance, and franchise investor models with legally compliant structures, all unified to support scalable and intelligent expansion. Today, this live franchise system is actively powering the rollout of 200 international elegant hoopoe branches, backed by a DIFC-compliant legal foundation and protected under WIPO global intellectual property law. The launch of SEGA™ represents a significant shift in the global franchising paradigm from outdated disclosure documents to intelligent, operational ecosystems. At a time when businesses are navigating rapid digital transformation and rising investor expectations, SEGA™ offers a future-ready model that is systemised, scalable, and globally compliant - setting a new benchmark for the next generation of intelligent franchising.
Arabian Post
21-07-2025
- Arabian Post
Counterfeit and Refurbished Transducers Pose Serious Safety Risks
Merz Aesthetics® Hong Kong Launches Ultherapy® Authenticity Verification Reward Program This August Consumers Urged to Verify Ultherapy® Transducers Authenticity for Safe and Effective Treatments HONG KONG SAR & MACAU SAR – Media OutReach Newswire – 30 June 2025 – Merz Aesthetics®, the world's largest dedicated medical aesthetics business for more than 115 years, leads the industry shift with Ultherapy PRIME®, the latest innovation in hyper-personalized, non-invasive skin lifting., which have earned the trust and support of medical aesthetics professionals and consumers in Hong Kong and Macau. Recently, the emergence of counterfeit and refurbished transducers in the local markets pose serious potential risks to treatment results and patients' safety. Merz Aesthetics® Hong Kong urges consumers to verify the authenticity of Ultherapy® products and seek treatments exclusively at authorized clinics. Merz Aesthetics® Hong Kong will launch the Ultherapy® Authenticity Verification Reward Program this August — making it easy for consumers to verify the Systems and transducers, reinforcing confidence and safety in every treatment. Trusted Technology, Proven Results — Beware of Counterfeit Transducers ADVERTISEMENT Ultherapy® and its latest innovation, Ultherapy PRIME® (collectively 'Systems'), are manufactured in the United States and remain the only US FDA cleared non-invasive micro-focused ultrasound skin lifting treatment with real-time visualization.. Ultherapy® DeepSEE® transducers are available in 4.5mm, 3.0mm, and 1.5mm depths to target different layers of the skin. The real-time imaging allows practitioners to visualize skin structure and tissue layers during treatment, ensuring that energy is precisely delivered to the intended depth of the skin for safe and effective results. Each Ultherapy® DeepSEE® transducer is designed to deliver a designated 2,400 dosage lines and cannot be recharged or refurbished once depleted. The recent emergence of counterfeit or refurbished transducers in the market has raised serious concerns over treatment results and patients' safety. Inaccurate energy delivery into the skin will compromise lifting results and create extremely high risks, potentially leading to burns. The use of counterfeit or refurbished transducers can also impair the Systems, potentially leading to unpredictable outcomes that may cause harm to patients. Authentic Transducers Are Traceable — Counterfeit Unknown Every Ulthera® DeepSEE® transducers carries a unique serial number and QR code, allowing it to be traced back to the purchasing clinic. Counterfeit or refurbished transducers often fail QR verification, raising questions about their origin and posing significant safety risks. In addition, every authentic transducer has a specified shelf-life which is12 months from the date of manufacture. Expired transducers should not be used, as they may result in unpredictable outcomes which can possibly harm or injure the patients because there is no clinical evidence to support the use of such expired transducers. Choose Only Authorized Ultherapy® Clinics ADVERTISEMENT Our official Ultherapy® website ( regularly updates the list of clinics and medical aesthetic centers that use authentic Systems and transducers. Each authorized provider receives official certificates for in-clinic display. Merz Aesthetics® urges consumers to choose authentic Ultherapy® treatments from officially authorized clinics and aesthetic centers to ensure that only certified Systems and transducers are used. Products obtained through unauthorized or parallel import channels may not comply with the manufacturer's prescribed storage and handling standards, potentially compromising safety and efficacy. 3-Step Verification Program Launches This August To help consumers easily identify authentic Systems and transducers, Merz Aesthetics® Hong Kong is launching the Ultherapy® Authenticity Verification Reward Program in August 2025. With just three simple steps, consumers can authenticate products and enjoy a special reward: 1. Scan the QR code on the System to verify authenticity. Counterfeit machines typically lack valid QR verification. 2. Take a photo of the QR code on the transducer and upload it to the official website for instant verification. 3. Successfully complete both verifications to receive a HK$100 Häagen-Dazs coupon as your reward (limited quantities, available in Hong Kong only). Report Suspected Counterfeit or Refurbished Devices Merz Aesthetics® Hong Kong will continue to take enforcement action against the sale or use of counterfeit version of the Ultherapy® and Ultherapy PRIME® systems, as well as unauthorized, refurbished, or counterfeit transducers. The company also warns against any unauthorized modifications or repairs of the Systems. Only authorized representatives and service centers, certified by the manufacturer, are properly trained and qualified to inspect, repair, or replace components of the Systems. Merz Aesthetics® Hong Kong believes that the patients' well-being and treatments safety are core values shared with its network of professional medical partners. We urge both providers and consumers to report any suspected use of counterfeit systems, counterfeit transducers, or refurbished transducers. Consumers are encouraged to consult the official Ultherapy® website ( for a list of authorized clinics before treatment. With the launch of the Ultherapy® Authenticity Verification Reward Program this August 2025, they can also complete a simple verification process to confirm that both the Systems and transducers are authentic ensuring every session is safe, effective, and provides piece of mind. Hashtag: #MerzAesthetics The issuer is solely responsible for the content of this announcement. About Ultherapy® /Ultherapy PRIME® Ultherapy® , The noninvasive Ultherapy® procedure is U.S. FDA-cleared to lift skin on the neck, on the eyebrow and under the chin as well as to improve lines and wrinkles on the décolletage, with over 3 million treatments performed worldwide. Using micro-focused ultrasound energy with real-time visualization (MFU-V), Ultherapy® can see deep within the layers of the skin and enable treatment plan to be hyper-personalized. A single treatment provides results lasting up to one year with no downtime.1,2,3,4,5,6,7. Ultherapy PRIME® is the latest innovation version of Ultherapy®, recognized as the gold standard for non-surgical lifting and skin tightening. Learn more about Ultherapy® treatments at About Merz Aesthetics® Merz Aesthetics® is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient's needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics® is known for building unique connections with customers who feel like family. Merz Aesthetics®' global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at References: 1. Ulthera® Instructions for SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432. 2. Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel's Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79. 3. Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33. 4. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality – A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518. 5. Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting. 6. White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29. 7. Data on File.
Arabian Post
12-07-2025
- Arabian Post
Singapore Welcomes Wegovy® as a New Prescription Weight‑Loss Option
A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a chronic disease. The product, from Novo Nordisk, is licensed for adults and those aged 12 and above who are obese or overweight with at least one weight‑related condition such as hypertension, type 2 diabetes or dyslipidemia. The drug works by mimicking the gut hormone GLP‑1, promoting a sense of fullness and reducing food intake when combined with healthier diet and exercise regimes. Its introduction follows approval by the Health Sciences Authority on 28 February 2025 for use among adolescents with obesity—a first in the region. Over 600,000 adult Singaporeans are classified as obese, a figure that underlines the public health urgency given the hundreds of comorbidities associated with obesity. The rollout of Wegovy® offers a medically guided therapy for a condition too often dismissed as a lifestyle issue. ADVERTISEMENT Clinical experts argue obesity stems from complex biological factors, ranging from genetics to hormonal imbalances. Dr Abel Soh, chair of the Endocrine and Metabolic Society of Singapore, says, 'Obesity is not simply the result of lifestyle choices—it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones and environment'. Approval comes amid global strain on semaglutide supplies. Local clinics previously stocked Ozempic and Rybelsus and faced intermittent shortages, with expectant Wegovy® shipments deferred until 2026 according to some medical guides. Private clinics were unable to reference branded drugs until local stock arrived, due to regulatory restrictions. Available through prescription in private settings, Wegovy® will be offered alongside diet and exercise interventions. The injectable is indicated for chronic use; ongoing physician oversight is advised. Regulatory approval includes a requirement to review treatment after 12 weeks in adolescents if BMI reduction falls below 5% on the full 2.4 mg dose. Globally, Wegovy® was first authorised in the US in June 2021, followed by EU approval in early 2022. Earlier, in Singapore, semaglutide received approval under Ozempic's label starting March 2023 for diabetic therapy. The drug's effectiveness has been supported by the STEP clinical programmes, showing average weight reductions of between 10–15% over periods of 68 to 104 weeks. Benefits extend beyond weight loss to metabolic health improvements, including lower blood pressure and decreased cholesterol. Local uptake may mirror global patterns, where appetite suppression and metabolic regulation paired with lifestyle changes have delivered sustainable weight loss without surgery. However, supply challenges persist: healthcare providers warn that stocks may remain tight, with some expect delays or patient referrals under the Ozempic brand. Novo Nordisk has also updated its savings programme for Wegovy®, making it more accessible to cash‑paying patients. The initiative aims to reduce financial barriers, although uptake and cost‑effectiveness will depend on real‑world pricing and insurance coverage.
